The vaccine, which is designed to work through early inhibition of amyloid beta depositions, is due to enter Phase I trials next year.
It's a "he said, she said" situation over the true value of Astex Pharmaceuticals. An activist shareholder has thrown up a roadblock for a proposed $886 million bid from Otsuka that it thinks is too low, accusing Astex of failing to reach out to all potential bidders--claims the company denies.
Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases--the most nods it's given in a single meeting all year.
Just a few days after Astex reported positive mid-stage data on a lead cancer therapy, Japan's Otsuka has snapped up the U.S. biotech and its slate of experimental cancer drugs for $886 million cash. Astex shares soared yesterday afternoon as the news spread ahead of the official announcement.
Lundbeck and Otsuka are quickly ramping up a 3,000-patient Phase III study for an experimental Alzheimer's drug after claiming success in improving cognition among a group of patients taking the treatment alongside donepezil for 24 weeks in a Phase II trial.
Building on an earlier alliance, Otsuka has gained co-development and co-promotion rights in the U.S., Japan and Europe for Lu AE58054, an experimental Alzheimer's drug now in position for a looming pivotal program.
GW Pharmaceuticals, the U.K. biotech which is commercializing a cannabis-based drug for multiple sclerosis, says their research collaboration with Otsuka has produced a promising new drug candidate for epilepsy.
Lundbeck and its partner Otsuka have put their bid for an approval of their long-acting version of the antipsychotic drug Abilify back on the regulatory track. The partners on aripiprazole say that the FDA has accepted their resubmission for the treatment and set a PDUFA deadline for the end of February in 2013.
U.S. regulators have delayed the potential launch of a once-monthly version of the blockbuster antipsychotic Abilify. Otsuka Pharmaceutical and partner H. Lundbeck broke the bad news today that the FDA handed the companies a complete response letter (CRL), saying deficiencies were uncovered in an inspection of a third-party supplier of sterile water for making the drug.
As drug-resistant cases of tuberculosis rage, Otsuka has impressed doctors with a developmental drug that has shown an ability to wipe out strains of the airborne bug that have immunity to existing treatments.